+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2030

  • ID: 5118880
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 200 pages
  • DelveInsight

FEATURED COMPANIES

  • Italfarmaco
  • Promedior/Roche
  • Protagonist Therapeutics
  • MORE
Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Polycythemia Vera , historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Polycythemia Vera market report provides current treatment practices, emerging drugs, Polycythemia Vera market share of the individual therapies, current and forecasted Polycythemia Vera market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Polycythemia Vera treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Polycythemia Vera Disease Understanding and Treatment Algorithm

Polycythemia Vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person's lifetime.

PV is diagnosed by testing the blood for levels of a hormone called erythropoietin as well as testing the blood for mutations in JAK2 or TET2. If mutations are not found in the red blood cells but the doctors still suspect a diagnosis of polycythemia vera, a bone marrow biopsy may be done to look for mutations in the hematopoietic blood cells which are located in the bone marrow.

The most precarious symptom of polycythemia vera is the chance for a thrombotic event that can cause a heart attack or stroke. There is also a small chance that polycythemia vera could cause an individual to develop leukemia. With proper treatment, however, these symptoms have not been shown to greatly affect the expected lifespan of a person with polycythemia vera. Another complication i.e. itching (pruritus) patients can manage with the help of various medicines.

Diagnosis

PV is usually diagnosed in the average age of people 60-65 years. It is uncommon in people under the age of 40. PV develops more often in men than in women. Most people with PV do not have a family history of this disease. In the early stages, there are not any specific signs and symptoms. When too many RBCs and platelets build up in the blood, symptoms start to appear. Headache, dizziness, fatigue, blurred vision or blind spots, shortness of breath, itchy skin, spleen enlargement (Splenomegaly) blood clot, heavy bleeding, and others are the symptoms of PV. The diagnosis of PV is done by testing the blood for levels of a hormone called erythropoietin or testing the blood for mutations in JAK2. Bone marrow aspiration and biopsy are also done to confirm whether or not a person has PV. The diagnostic test also includes Complete blood count (CBC) to measure the number and quality of WBCs, RBCs, and platelets.

Continued in the report…..

Treatment

The treatment for PV is based on the symptoms and progression, as well as, the age of the patients. The goal of treatments for PV is to control symptoms and lower the risk of complications. Treatments like phlebotomy help to make the blood thinner when there are too many red blood cells. It is done in the same way as donating blood and drugs like hydroxyurea, interferon alfa, etc. are used. Various other supportive therapies antihistamines, allopurinol, aspirin are also recommended.

For the low-risk patients (age < 60years, no history of thrombosis) phlebotomy and low-dose aspirin are recommended. For the high-risk patient (age ≥60 years), the first-line of therapy is hydroxyurea or interferon. The second line of therapy for these patients include Jak2 inhibitor, busulfan, pipobroman, and 32P.

Enlargement of the spleen sometimes cause pain and problem to the patients, and for that surgery is done to remove the spleen (splenectomy). No single treatment is effective for all individuals. The prognosis of PV largely depends on whether a patient receives treatment or not. Treatment helps reduce the risk of life-threatening complications like myelofibrosis, heart attack, ischemic stroke, pulmonary embolism, portal hypertension, acute myeloid leukemia. These complications from PV are possible even with treatment, but the risk is much lower.

Polycythemia Vera Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of PV, Prevalence Population of PV Based on Symptoms, Gender-specific Symptomatic Prevalence of PV, Age-specific Symptomatic Prevalence of PV, Prevalence of PV Based on Risk, and Prevalence of PV by Gene Mutation scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

The total prevalent population of PV in the 7MM was 283,442 in 2017.

The estimates show the highest prevalence of PV in the United States with 157,290 cases in 2017.

The epidemiology model for PV estimates that out of the total population of 157,290 cases in the US for PV, 62,916 cases and 94,374 cases were contributed by asymptomatic and symptomatic, respectively.

Among the European five countries, Germany had the highest symptomatic prevalent population of PV with 14,502 cases, followed by France and the United Kingdom.

Japan had 18,954 symptomatic prevalent cases for PV in 2017.

Japan accounts second among the 7MM in terms of prevalent cases with 31,589 cases among the 7MM.

Country Wise- Polycythemia Vera Epidemiology

The epidemiology segment also provides the Polycythemia Vera epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Polycythemia Vera Drug Chapters

Drug chapter segment of the Polycythemia Vera report encloses the detailed analysis of Polycythemia Vera marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Polycythemia Vera clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Jakafi, Jakavi (Ruxolitinib): Incyte Corporation/Novartis

Jakafi is a kinase inhibitor developed by Incyte Corporation/Novartis, designated for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis, post-Polycythemia Vera (PV) myelofibrosis and post-essential thrombocythemia myelofibrosis in adults. This drug is also approved for adult patients of PV who have had a poor response to hydroxyurea. It is approved in the US, EU and Japan for the treatment of PV.

Jakafi is also approved for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Some trials of the Ruxolitinib are ongoing in phase III and phase II clinical trials for the treatment of PV.

Product detail in the report.

Besremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentia

Besremi (ropeginterferon alfa-2B/AOP2014/P1101) is mono-pegylated proline interferon approved as first-line monotherapy in adults for the treatment of PV without symptomatic splenomegaly. It is long-acting, mono-pegylated proline interferon developed using PharmaEssentia's novel pegylation technology platform.

Besremi has been shown to induce complete hematologic and high clinical response rates with good tolerability, as well as high molecular response rates and disease-modifying capabilities, which may result in a delay of disease progression. It also showed high molecular response rates, associated with the ability to reduce the allelic burden of both mutant JAK2 and importantly also non JAK2 mutations, which are believed to play a role in disease progression. It is currently approved in the EU and data from AOP´s development program will be presented to the US FDA for approval for commercialization in the US by PharmaEssentia.

Product detail in the report.

Polycythemia Vera Emerging Drugs

Givinostat: Italfarmaco

Givinostat (ITF2357) is an orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.

Patients with PV have abnormalities in a gene that is responsible for the production of an enzyme known as Janus kinase 2 (JAK2). JAK2 is involved in the reproduction and growth of red blood cells. In PV, JAK2 is over-activated. Givinostat is thought to work by reducing the levels of JAK2. In patients with polycythemia, the reduction of mutant JAK2 concentrations by givinostat is believed to slow down the abnormal growth of erythrocytes and ameliorate the symptoms of the disease. The company is investigating givinostat in phase II clinical trials in patients with PV.

Product detail in the report.

PTG-300: Protagonist Therapeutics

PTG-300 is an injectable compound that mimics the effect of the natural hormone hepcidin, but with greater potency, solubility, and stability. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. As a hepcidin mimetic, PTG-300 may redistribute iron to the macrophages, reduce iron-induced oxidative stress in the bone marrow, and allow sufficient production of red blood cells. Also, by limiting the release of iron into the blood, PTG-300 may inhibit the damage caused by excessive absorption of iron by vital organs such as the liver and heart.

Protagonist Therapeutics is currently developing PTG-300 for beta-thalassemia (non-transfusion dependent and transfusion-dependent), polycythemia vera, hereditary hemochromatosis, and myelodysplastic syndromes. The company has announced initial phase II results of PTG-300 in the treatment of PV.

Product detail in the report.

PRM-151: Promedior/Roche

PRM-151 is a recombinant form of the endogenous human innate immunity protein pentraxin-2 (PTX-2), which is specifically active at the site of tissue damage. PRM-151 is an agonist that acts as a macrophage polarization factor to prevent and potentially reverse fibrosis (PR Newswire, 2019).

PRM-151 prevents reverse fibrosis in animal models of myelofibrosis (MF) by targeting the differentiation of fibrocytes (essential cells in the fibrotic process) from monocytes (Verstovsek et al., 2018).

Promedior is currently evaluating PRM-151 in phase II clinical trial in the subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV MF), and post-essential thrombocythemia MF (Post-ET MF).

Product detail in the report.

List to be continued in the report…

Polycythemia Vera Market Outlook

The therapeutic market of PV in the seven major markets was assessed to be USD 951.68 Million in 2017 and is expected to grow during the study period (2017-2030).

Cytoreductive therapies have been used in older patients and those with a history of thrombosis to achieve these goals. Hydroxyurea (HU) remains the first-line cytoreductive choice; however, up to one in four patients treated with HU over time will develop resistance or intolerance to HU and go for the second-line therapy. More importantly, patients who fail HU have a 5.6-fold increase in mortality and a 6.8-fold increased risk of transformation to myelofibrosis or AML; therefore, alternative therapies are needed for these patients. Interferon-α has been used in PV and has shown significant activity in achieving hematologic responses and decreasing the JAK2 V617F mutation allele burden. JAK inhibition has also been investigated and recently garnered regulatory approval for this indication.

The outcomes of PV patients who fail or are intolerant of hydroxyurea are poor. Although pegylated interferon can be considered in younger patients, currently, ruxolitinib is the only US FDA approved agent in this setting, representing a viable option, leading to hematocrit control and a reduction in spleen size and constitutional symptoms. Although a small number of patients achieve a molecular response with continuous treatment, the implications of such a response to the clinical outcomes are still unknown. Patients whose disease is not adequately controlled with ruxolitinib, or who lose their response, can be treated with low-dose busulfan or pipobroman; however, they should be encouraged to participate in trials with novel therapies.

The treatment for PV has been classified as first-line and second-line treatment. Of the current treatment regimens, hydroxyurea (alone or along with Phlebotomy), and aspirin constitute the first-line treatment therapies. The second-line treatment for patients who are intolerant to hydroxyurea constitutes the only approved drug in the US, Jakafi, and other therapies such as anagrelide, and interferon-alpha (such as PEG-Intron and Pegasys)

Furthermore, the second-line therapies primarily constitute the only approved drug, Jakafi, and other therapies such as anagrelide, and interferon-alpha. Among these, Jakavi contributed the highest share in the PV market in 2017 in the 7MM.

Of the emerging therapies for the second-line treatment, companies like Protagonist Therapeutics, Italfarmaco, and Imago BioSciences are expected to enter the treatment market, with their respective products, during the forecast period [2020-2030]. Givinostat and PTG-300 in the upcoming years will create a significant impact in its launch year.

Out of the emerging therapies, Besremi (AOP Orphan Pharmaceuticals AG/PharmaEssentia), which is an interferon-alpha 2b stimulant, and has already approved in the European countries, will enter the market for PV as a first-line treatment, thereby giving a stiff competition to hydroxyurea, which is the mainstay for treatment in patients with PV. It is approved recently (2019) in European countries and expected to launch in the United States and Japan by 2021 and 2022, respectively.

The market size of PV has been assessed to undergo tough competition, wherein Jakafi is likely to maintain dominance in the hydroxyurea-refractory (second line) PV market. On the other hand, Besremi represents an even small risk, as the drug is being positioned in first-line treatment for PV vs. hydroxyurea.

According to the publisher, the PV market is expected to change in the study period 2017-2030.

Key Findings

The market size of PV in the 7MM was USD 951.68 million in 2017.

Of the current treatment regimens, hydroxyurea (alone or along with Phlebotomy), and aspirin constitute the first-line treatment. Furthermore, the second-line therapies primarily constitute Jakafi (Jakavi) and other therapies such as anagrelide, and interferon-alpha. Among these, Jakafi contributed the highest share in the PV market (USD 556.54 million) in 2017 in the 7MM.

Of the emerging therapies for the second-line treatment, Protagonist Therapeutics, Italfarmaco, and Imago BioSciences are expected to enter the treatment market, with their respective products, during the forecast period [2020-2030].

The United States Market Outlook

This section provides the total Polycythemia Vera market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Polycythemia Vera market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Polycythemia Vera market size and market size by therapies in Japan is also mentioned.

Polycythemia Vera Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to get launched in the market during the study period 2017-2030. The analysis covers Polycythemia Vera market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Polycythemia Vera Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Polycythemia Vera key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Polycythemia Vera emerging therapies.

Reimbursement Scenario in Polycythemia Vera

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Polycythemia Vera domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Polycythemia Vera market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Polycythemia Vera Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Polycythemia Vera , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Polycythemia Vera epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Polycythemia Vera are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Polycythemia Vera market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Polycythemia Vera market
Report Highlights
  • In the coming years, Polycythemia Vera market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Polycythemia Vera R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Polycythemia Vera . Launch of emerging therapies will significantly impact the Polycythemia Vera market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Polycythemia Vera
This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Polycythemia Vera Report Insights

Patient Population
Therapeutic Approaches
Polycythemia Vera Pipeline Analysis
Polycythemia Vera Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Polycythemia Vera Report Key Strengths

11 Years Forecast
7MM Coverage

Polycythemia Vera Epidemiology Segmentation

Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Polycythemia Vera Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions Answered

Market Insights:

What was the Polycythemia Vera market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Polycythemia Vera total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Polycythemia Vera market size during the forecast period (2017-2030)?
At what CAGR, the Polycythemia Vera market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Polycythemia Vera market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Polycythemia Vera market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Polycythemia Vera ?
What is the historical Polycythemia Vera patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Polycythemia Vera in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Polycythemia Vera ?
Out of all 7MM countries, which country would have the highest prevalent population of Polycythemia Vera during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Polycythemia Vera treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Polycythemia Vera in the USA, Europe, and Japan?
What are the Polycythemia Vera marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Polycythemia Vera ?
How many therapies are developed by each company for Polycythemia Vera treatment?
How many are emerging therapies in mid-stage, and late stage of development for Polycythemia Vera treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Polycythemia Vera therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Polycythemia Vera and their status?
What are the key designations that have been granted for the emerging therapies for Polycythemia Vera ?
What are the global historical and forecasted market of Polycythemia Vera ?

Reasons to Buy

The report will help in developing business strategies by understanding trends shaping and driving the Polycythemia Vera market
To understand the future market competition in the Polycythemia Vera market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Polycythemia Vera in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Polycythemia Vera market
To understand the future market competition in the Polycythemia Vera market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Italfarmaco
  • Promedior/Roche
  • Protagonist Therapeutics
  • MORE
1. Key Insights

2. Executive Summary of Polycythemia Vera (PV)

3. Polycythemia Vera (PV) Market Overview at a Glance
3.1. Market (%) Distribution of PV in 2017
3.2. Market (%) Distribution of PV in 2030

4. Polycythemia Vera (PV): Disease Background and Overview
4.1. Introduction
4.2. Polycythemia Vera: A Type of MPN
4.3. Signs and Symptoms of Polycythemia Vera
4.4. Causes of Polycythemia Vera
4.5. Complications due to Polycythemia Vera
4.6. Clinical Aspects of Polycythemia Vera
4.7. Pathophysiology of Polycythemia Vera
4.7.1. JAK2 V617F in Polycythemia Vera
4.8. Diagnosis of Polycythemia Vera
4.9. Diagnostic Guidelines
4.9.1. British Society for Haematology Guidelines for Polycythemia Vera (PV)
4.9.2. WHO Diagnostic Guidelines
4.9.3. British Society for Haematology Guideline

5. Case Reports
5.1. The role of advanced practitioners in optimizing clinical management and support of patients with polycythemia vera
5.2. A case study on polycythemia vera: diagnosis through CBC management with ruxolitinib
5.3. A case of severe dermatitis in a patient with polycythemia vera during cytoreductive therapy
5.4. Perioperative management of polycythemia vera with advanced gastric cancer: a case report

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Prevalent Population of Polycythemia Vera in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. KOL Insights
7.3. Total Prevalent Population of Polycythemia Vera in the United States
7.4. Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in the United States
7.5. Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the United States
7.6. Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the United States
7.7. Prevalence of Polycythemia Vera (PV) Based on Risk in the United States
7.8. Prevalence of PV by Gene Mutation in the United States

8. EU5 Epidemiology
8.1. KOL Insights
8.2. Germany Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Total Prevalent Population of Polycythemia Vera in Germany
8.2.3. Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Germany
8.2.4. Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany
8.2.5. Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany
8.2.6. Prevalence of Polycythemia Vera (PV) Based on Risk in Germany
8.2.7. Prevalence of PV by Gene Mutation in Germany
8.3. France Epidemiology
8.3.1. Assumptions and rationale
8.3.2. Total Prevalent Population of Polycythemia Vera in France
8.3.3. Prevalent Population of Polycythemia Vera Based on Symptoms in France
8.3.4. Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France
8.3.5. Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France
8.3.6. Prevalence of Polycythemia Vera (PV) Based on Risk in France
8.3.7. Prevalence of PV by Gene Mutation in France
8.4. Italy Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Prevalent Population of Polycythemia Vera in Italy
8.4.3. Prevalent Population of Polycythemia Vera Based on Symptoms in Italy
8.4.4. Gender-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy
8.4.5. Age-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy
8.4.6. Prevalence of Polycythemia Vera (PV) Based on Risk in Italy
8.4.7. Prevalence of PV by Gene Mutation in Italy
8.5. Spain Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Prevalent Population of Polycythemia Vera in Spain
8.5.3. Prevalent Population of Polycythemia Vera Based on Symptoms in Spain
8.5.4. Gender-specific Prevalence of Polycythemia Vera in Spain
8.5.5. Age-specific Prevalence of Polycythemia Vera in Spain
8.5.6. Prevalence of Polycythemia Vera (PV) Based on Risk in Spain
8.5.7. Prevalence of PV by Gene Mutation in Spain
8.6. United Kingdom Epidemiology
8.6.1. Assumptions and Rationale
8.6.2. Total Prevalent Population of Polycythemia Vera in the United Kingdom
8.6.3. Prevalent Population of Polycythemia Vera Based on Symptoms in the United Kingdom
8.6.4. Gender-specific Prevalence of Polycythemia Vera in the United Kingdom
8.6.5. Age-specific Prevalence of Polycythemia Vera in the United Kingdom
8.6.6. Prevalence of Polycythemia Vera (PV) Based on Risk in the United Kingdom
8.6.7. Prevalence of PV by Gene Mutation in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. KOL Insights
9.3. Total Prevalent Population of Polycythemia Vera in Japan
9.4. Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Japan
9.5. Gender-specific Prevalence of Polycythemia Vera in Japan
9.6. Age-specific Prevalence of Polycythemia Vera in Japan
9.7. Prevalence of Polycythemia Vera (PV) Based on Risk in Japan
9.8. Prevalence of PV by Gene Mutation in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices
10.1. Treatment Algorithm
10.2. Proposed Guidelines for Polycythemia Vera
10.3. A British Society for Haematology Guidelines for PV
10.4. National Comprehensive Cancer Network (NCCN) Guidelines for Polycythemia Vera (PV)
10.5. European Society for Medical Oncology Guidelines for Polycythemia Vera

11. Unmet Needs

12. Marketed Products
12.1. Jakafi (Ruxolitinib): Incyte Corporation/Novartis
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Clinical Development
12.1.4. Safety and Efficacy
12.1.5. Product Description
12.2. Besremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentia
12.2.1. Product Description
12.2.2. Mechanism of Action
12.2.3. Regulatory Milestones
12.2.4. Advantages and Disadvantages
12.2.5. Clinical Development
12.2.6. Safety and Efficacy
12.2.7. Product Profile

13. Emerging Therapies
13.1. KRT-232: Kartos Therapeutics
13.1.1. Product Description
13.1.2. Clinical Development
13.1.3. Clinical Trials Information
13.1.4. Product Profile
13.2. Givinostat: Italfarmaco
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Advantages and Disadvantages
13.2.4. Clinical Development
13.2.5. Clinical Trials Information
13.2.6. Safety and Efficacy
13.2.7. Product Profile
13.3. PTG-300: Protagonist Therapeutics
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. PRM-151: Promedior/Roche
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
13.5. Imetelstat (GRN163L): Geron Corporation
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Product Profile
13.6. Bomedemstat (IMG-7289): Imago BioSciences
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Product Profile

14. Polycythemia Vera (PV): 7MM Market Analysis
14.1. Key Findings
14.2. Market Methodology
14.3. Market Size of Polycythemia Vera in the 7MM
14.4. Market Size of Polycythemia Vera by Therapies in the 7MM

15. United States: Market Outlook
15.1. United States Market Size
15.1.1. Total Market size of Polycythemia Vera in the United States
15.1.2. Market Size of Polycythemia Vera by Therapies in the US

16. EU-5 countries: Market Outlook
16.1. Germany Market Size
16.1.1. Total Market size of Polycythemia Vera in Germany
16.1.2. Market Size of Polycythemia Vera by therapies in Germany
16.2. France Market Size
16.2.1. Total Market size of Polycythemia Vera in France
16.2.2. Market Size of Polycythemia Vera by therapies in France
16.3. Italy Market Size
16.3.1. Total Market size of Polycythemia Vera in Italy
16.3.2. Market Size of Polycythemia Vera by therapies in Italy
16.4. Spain Market Size
16.4.1. Total Market size of Polycythemia Vera in Spain
16.4.2. Market Size of Polycythemia Vera by therapies in Spain
16.5. United Kingdom Market Size
16.5.1. Total Market size of Polycythemia Vera in the United Kingdom
16.5.2. Market Size of Polycythemia Vera by therapies in the UK

17. Japan Market Outlook
17.1. Japan Market Size
17.1.1. Total Market size of Polycythemia Vera in Japan
17.1.2. Market Size of Polycythemia Vera by therapies in Japan

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Reimbursement and Market Access

22. Appendix
22.1. Report Methodology

23. Publisher Capabilities

24. Disclaimer

25. About the Publisher
List of Tables
Table 1: Summary of Polycythemia Vera, (PV), Market, Epidemiology and Key Events (2017-2030)

Table 2: Thrombotic Complications in Polycythemia Vera

Table 3: Evidence statements and grades of recommendations

Table 4: Proposed modified criteria for the diagnosis of Polycythemia Vera

Table 5: Stage 1 and 2 investigations in patients with an absolute Erythrocytosis

Table 6: World Health Organization diagnostic criteria for Polycythemia Vera

Table 7: Recommended diagnostic criteria for Polycythemia Vera

Table 8: Management of Polycythemia Vera

Table 9: Total Prevalent Population of Polycythemia Vera in the 7MM (2017-2030)

Table 10: Total Prevalent Population of Polycythemia Vera in the US (2017-2030)

Table 11: Prevalent Population of Polycythemia Vera Based on Symptoms in the US (2017-2030)

Table 12: Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)

Table 13: Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)

Table 14: Prevalence of Polycythemia Vera Based on Risk in the US (2017-2030)

Table 15: Prevalence of PV by Gene Mutation in the US (2017-2030)

Table 16: Total Prevalent Population of Polycythemia Vera in Germany (2017-2030)

Table 17: Prevalent Population of Polycythemia Vera Based on Symptoms in Germany (2017-2030)

Table 18: Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)

Table 19: Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)

Table 20: Prevalence of Polycythemia Vera Based on Risk in Germany (2017-2030)

Table 21: Prevalence of PV by Gene Mutation in Germany (2017-2030)

Table 22: Total Prevalent Population of Polycythemia Vera in France (2017-2030)

Table 23: Prevalent Population of Polycythemia Vera Based on Symptoms in France (2017-2030)

Table 24: Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)

Table 25: Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)

Table 26: Prevalence of Polycythemia Vera Based on Risk in France (2017-2030)

Table 27: Prevalence of PV by Gene Mutation in France (2017-2030)

Table 28: Total Prevalent Population of Polycythemia Vera in Italy (2017-2030)

Table 29: Prevalent Population of Polycythemia Vera Based on Symptoms in Italy (2017-2030)

Table 30: Gender-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)

Table 31: Age-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)

Table 32: Prevalence of Polycythemia Vera Based on Risk in Italy (2017-2030)

Table 33: Prevalence of PV by Gene Mutation in Italy (2017-2030)

Table 34: Total Prevalent Population of Polycythemia Vera in Spain (2017-2030)

Table 35: Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Spain (2017-2030)

Table 36: Gender-specific Prevalence of Polycythemia Vera in Spain (2017-2030)

Table 37: Age-specific Prevalence of Polycythemia Vera in Spain (2017-2030)

Table 38: Prevalence of Polycythemia Vera Based on Risk in Spain (2017-2030)

Table 39: Prevalence of PV by Gene Mutation in Spain (2017-2030)

Table 40: Total Prevalent Population of Polycythemia Vera in the United Kingdom (2017-2030)

Table 41: Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in the UK (2017-2030)

Table 42: Gender-specific Prevalence of Polycythemia Vera in the UK (2017-2030)

Table 43: Age-specific Prevalence of Polycythemia Vera in the UK (2017-2030)

Table 44: Prevalence of Polycythemia Vera Based on Risk in the UK (2017-2030)

Table 45: Prevalence of PV by Gene Mutation in the UK (2017-2030)

Table 46: Total Prevalent Population of Polycythemia Vera in Japan (2017-2030)

Table 47: Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Japan (2017-2030)

Table 48: Gender-specific Prevalence of Polycythemia Vera in Japan (2017-2030)

Table 49: Age-specific Prevalence of Polycythemia Vera in Japan (2017-2030)

Table 50: Prevalence of Polycythemia Vera Based on Risk in Japan (2017-2030)

Table 51: Prevalence of PV by Gene Mutation in Japan (2017-2030)

Table 52: Symptomatic Treatments in Polycythemia Vera

Table 53: Myelosuppressive Agents for the Treatment of Polycythemia Vera

Table 54: Risk stratification for PV

Table 55: IGW-MRT and ELN Response Criteria for Polycythemia Vera (PV)

Table 56: Jakafi (Ruxolitinib), Clinical Trial Description, 2020

Table 57: Besremi, Clinical Trial Description, 2020

Table 58: KRT-232, Clinical Trial Description, 2020

Table 59: Givinostat, Clinical Trial Description, 2020

Table 60: PTG-300, Clinical Trial Description, 2020

Table 61: PRM-151, Clinical Trial Description, 2020

Table 62: Imetelstat (GRN163L), Clinical Trial Description, 2020

Table 63: Bomedemstat (IMG-7289), Clinical Trial Description, 2020

Table 64: Market Size of Polycythemia Vera in the 7MM, USD Million (2017-2030)

Table 65: Market Size of Polycythemia Vera by therapies in the 7MM, USD Million (2017-2030)

Table 66: Expected Launch Date of Emerging Drugs in the United States

Table 67: Market Size of Polycythemia Vera in the US, USD Million (2017-2030)

Table 68: Market Size of Polycythemia Vera by therapies in the United States, USD Million (2017-2030)

Table 69: Expected Launch Date of Emerging Drugs in EU-5 Countries

Table 70: Market Size of Polycythemia Vera in Germany, USD Million (2017-2030)

Table 71: Market Size of Polycythemia Vera by therapies in Germany, in USD Million (2017-2030)

Table 72: Market Size of Polycythemia Vera in France, USD Million (2017-2030)

Table 73: Market Size of Polycythemia Vera by therapies in France, in USD Million (2017-2030)

Table 74: Market Size of Polycythemia Vera in Italy, USD million (2017-2030)

Table 75: Market Size of Polycythemia Vera by therapies in Italy, in USD million (2017-2030)

Table 76: Market Size of Polycythemia Vera in Spain, USD million (2017-2030)

Table 77: Market Size of Polycythemia Vera by therapies in Spain, in USD million (2017-2030)

Table 78: Market Size of Polycythemia Vera in the UK, USD million (2017-2030)

Table 79: Market Size of Polycythemia Vera by therapies in the United Kingdom, in USD million (2017-2030)

Table 80: Expected Launch Date of Emerging Drugs in Japan

Table 81: Market Size of Polycythemia Vera in Japan, USD million (2017-2030)

Table 82: Market Size of Polycythemia Vera by therapies in Japan, in USD Million (2017-2030)

List of Figures
Figure 1: Types of Myeloproliferative Neoplasm (MPN)

Figure 2: Classification of Polycythemia

Figure 3: Affected areas and associated symptoms

Figure 4: Risk factors of PV

Figure 5: Schematic representation of the Epo-mediated signaling pathway

Figure 6: JAK/STAT Pathway in MPN

Figure 7: Scheme of the IGF-I/IGFBP-1-induced intracellular pathway that leads to inhibition of apoptosis.

Figure 8: Structure of Janus Kinases

Figure 9: Impact of JAK2 V617F Allele

Figure 10: Histopathologic spectrum of two recognized stages of Polycythemia Vera

Figure 11: Diagnostic Methods

Figure 12: A modern diagnostic algorithm for suspected Polycythemia Vera

Figure 13: Changes in plasma or red cell volume in various states of polycythemia

Figure 14: Classification of the Absolute Erythrocytosis

Figure 15: Total Prevalent Population of Polycythemia Vera in the 7MM (2017-2030)

Figure 16: Total Prevalent Population of Polycythemia Vera in the US (2017-2030)

Figure 17: Prevalent Population of Polycythemia Vera Based on Symptoms in the US (2017-2030)

Figure 18: Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)

Figure 19: Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)

Figure 20: Prevalence of Polycythemia Vera Based on Risk in the US (2017-2030)

Figure 21: Prevalence of PV by Gene Mutation in the US (2017-2030)

Figure 22: Total Prevalent Population of Polycythemia Vera in Germany (2017-2030)

Figure 23: Prevalent Population of Polycythemia Vera Based on Symptoms in Germany (2017-2030)

Figure 24: Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)

Figure 25: Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)

Figure 26: Prevalence of Polycythemia Vera Based on Risk in Germany (2017-2030)

Figure 27: Prevalence of PV by Gene Mutation in Germany (2017-2030)

Figure 28: Total Prevalent Population of Polycythemia Vera in France (2017-2030)

Figure 29: Prevalent Population of Polycythemia Vera Based on Symptoms in France (2017-2030)

Figure 30: Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)

Figure 31: Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)

Figure 32: Prevalence of Polycythemia Vera Based on Risk in France (2017-2030)

Figure 33: Prevalence of PV by Gene Mutation in France (2017-2030)

Figure 34: Total Prevalent Population of Polycythemia Vera in Italy (2017-2030)

Figure 35: Prevalent Population of Polycythemia Vera Based on Symptoms in Italy (2017-2030)

Figure 36: Gender-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)

Figure 37: Age-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)

Figure 38: Prevalence of Polycythemia Vera Based on Risk in Italy (2017-2030)

Figure 39: Prevalence of PV by Gene Mutation in Italy (2017-2030)

Figure 40: Total Prevalent Population of Polycythemia Vera in Spain (2017-2030)

Figure 41: Prevalent Population of Polycythemia Vera Based on Symptoms in Spain (2017-2030)

Figure 42: Gender-specific Prevalence of Polycythemia Vera in Spain (2017-2030)

Figure 43: Age-specific Prevalence of Polycythemia Vera in Spain (2017-2030)

Figure 44: Prevalence of Polycythemia Vera Based on Risk in Spain (2017-2030)

Figure 45: Prevalence of PV by Gene Mutation in Spain (2017-2030)

Figure 46: Total Prevalent Population of Polycythemia Vera in the United Kingdom (2017-2030)

Figure 47: Total Prevalent Population of PV Based on Symptoms in the UK (2017-2030)

Figure 48: Gender-specific Prevalence of Polycythemia Vera in the UK (2017-2030)

Figure 49: Age-specific Prevalence of Polycythemia Vera in the UK (2017-2030)

Figure 50: Prevalence of Polycythemia Vera Based on Risk in the UK (2017-2030)

Figure 51: Prevalence of PV by Gene Mutation in the UK (2017-2030)

Figure 52: Total Prevalent Population of Polycythemia Vera in Japan (2017-2030)

Figure 53: Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Japan (2017-2030)

Figure 54: Gender-specific Prevalence of Polycythemia Vera in Japan (2017-2030)

Figure 55: Age-specific Prevalence of Polycythemia Vera PV in Japan (2017-2030)

Figure 56: Prevalence of Polycythemia Vera Based on Risk in Japan (2017-2030)

Figure 57: Prevalence of PV by Gene Mutation in Japan (2017-2030)

Figure 58: Available Treatments for PV

Figure 59: Algorithm for the Treatment of Polycythemia Vera

Figure 60: Current Treatment Algorithm for Polycythemia Vera

Figure 61: Treatment for Low-risk Polycythemia Vera

Figure 62: Treatment of High-risk Polycythemia Vera

Figure 63: European Leukemia Net criteria for the definition of resistance/intolerance to hydroxyurea in patients with Polycythemia Vera

Figure 64: Unmet Need for PV

Figure 65: Market Size of Polycythemia Vera in the 7MM in USD Million (2017-2030)

Figure 66: Market Size of Polycythemia Vera by therapies in the 7MM, in USD Million (2017-2030)

Figure 67: Market Size of Polycythemia Vera in the US, USD Millions (2017-2030)

Figure 68: Market Size of Polycythemia Vera by therapies in the United States, in USD Million (2017-2030)

Figure 69: Market Size of Polycythemia Vera in Germany, USD Millions (2017-2030)

Figure 70: Market Size of Polycythemia Vera by therapies in Germany, in USD Million (2017-2030)

Figure 71: Market Size of Polycythemia Vera in France, USD Millions (2017-2030)

Figure 72: Market Size of Polycythemia Vera by therapies in France, in USD Million (2017-2030)

Figure 73: Market Size of Polycythemia Vera in Italy, USD million (2017-2030)

Figure 74: Market Size of Polycythemia Vera by therapies in Italy in USD million (2017-2030)

Figure 75: Market Size of Polycythemia Vera in Spain, USD million (2017-2030)

Figure 76: Market Size of Polycythemia Vera by therapies in Spain in USD million (2017-2030)

Figure 77: Market Size of Polycythemia Vera in the UK, USD million (2017-2030)

Figure 78: Market Size of Polycythemia Vera by therapies in the UK in USD million (2017-2030)

Figure 79: Market Size of Polycythemia Vera in Japan, USD million (2017-2030)

Figure 80: Market Size of Polycythemia Vera by therapies in Japan in USD million (2017-2030)

Figure 81: Market Drivers

Figure 82: Market Barriers

Figure 83: SWOT analysis of Polycythemia Vera
Note: Product cover images may vary from those shown
  • Italfarmaco
  • Protagonist Therapeutics
  • Promedior/Roche
  • AOP Orphan Pharmaceuticals AG/ PharmaEssentia
  • Incyte Corporation/Novartis
Note: Product cover images may vary from those shown
Adroll
adroll